Open Access<p>Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice</p>
Author(s) -
Yan Zhao,
Huan Huan Wang,
Yang Yang,
Wendan Jia,
Tong Su,
Yuxin Che,
Yixin Feng,
Xuemei Yuan,
Xuelian Wang
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s275670
Subject(s) - cpg oligodeoxynucleotide , adjuvant , cpg site , immune system , mannose receptor , ctl* , tumor microenvironment , immunopotentiator , cancer research , chemistry , peptide vaccine , cd8 , microbiology and biotechnology , biology , immunology , epitope , antibody , biochemistry , macrophage , in vitro , gene expression , dna methylation , gene
Previously, we demonstrated the therapeutic efficacy of a human papillomavirus (HPV) vaccine, including HPV16 E7 peptide and CpG oligodeoxynucleotides (CpG ODN), against small TC-1 grafted tumors. Here, we developed an HPV16 E7 peptide and CpG ODN vaccine delivered using liposomes modified with DC-targeting mannose, Lip E7/CpG, and determined its anti-tumor effects and influence on systemic immune responses and the tumor microenvironment (TME) in a mouse large TC-1 grafted tumor model.